| Pazzola, Antonio |
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) |
|
|
| Recruiting | 2 | 49 | Europe | Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion | Gruppo Oncologico Italiano di Ricerca Clinica | Pulmonary Large-cell Neuroendocrine Carcinoma | 12/26 | 12/26 | | |
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). |
|
|
| Not yet recruiting | 2 | 142 | Europe | Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide | Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 08/28 | 06/29 | | |
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments |
|
|
| Recruiting | N/A | 10000 | Europe | | Consorzio Oncotech | Metastatic Breast Cancer | 06/23 | 12/25 | | |
| Recruiting | N/A | 1000 | Europe | | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l. | Breast Neoplasms, Pregnancy, Fertility Preservation | 11/27 | 11/32 | | |
